Immunotherapy in lung cancer: A case report and review of the literatureS. Picardo
Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therapy. Medical management is often associated with the development of treatment resistance leading ...
Advancing neoadjuvant immunotherapy for lung cancer The NEOSTAR trial is a key step on route to better outcomes; but the best approach is likely to be an individualized one, reflecting the many factors that influence treatment response. Michael Conroy ...
cancer vaccines, and T-cell therapy (Goradel et al., 2021a,2021b;Taefehshokr et al., 2020). For instance, the expression of programmed death-ligand 1 (PD-L1) and 2 (PD-L2) on macrophages and dendritic cells (DCs) and their interaction with PD-1 on T-cells lead to blunt T-cell...
Immune Checkpoint InhibitorsImmune checkpoint expression siteEnglish generic name for inhibitorsInhibitor trade nameThe type of tumor being treatedAdverse reactions PD-1 ICIsT cell, B cell, NK cell, Monocytes, Dendritic cell, Tumor cell Pembrolizumab Keytruda Non-small cell lung cancer, malignant melanoma...
Immunotherapy for cancer has undergone a rapid expansion in classes, agents, and indications. By utilizing aspects of the body’s innate immune system
Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review Importance A series of high-profile clinical trials for patients with resectable early-stage non-small cell lung cancer (NSCLC) have recently changed the s... HJ West,JY Kim - 《Jama Oncology》 被引量: 0发表: 2024...
Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383(9928):1561-1571. doi:10.1016/S0140-6736(13)62159-5 PubMedGoogle ScholarCrossref 16. McGuinness LA, Higgins JPT. Risk-of-bias ...
Article Open access 27 May 2020 New immune cell engagers for cancer immunotherapy Article 25 January 2024 References Oiseth, S. J. & Aziz, M. S. A.-E. Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead. J. Cancer Metastasis Treat. 3, 250–261 (...
There have been major advances in the immunotherapy of cancer in recent years, including the development of T cell engagers — antibodies engineered to redirect T cells to recognize and kill cancer cells — for the treatment of haematological malignancies. However, the field still faces several chal...